ProCE Banner Activity

My Take on Simplified Regimens for Individuals With HIV and End-Stage Renal Disease

Clinical Thought
Learn about new data presented at the IDWeek 2020 virtual conference on the use of bictegravir/emtricitabine/tenofovir alafenamide in individuals with HIV and end-stage renal disease on hemodialysis.

Released: December 11, 2020

Expiration: December 10, 2021

Share

Faculty

Eric S. Daar

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by:

Janssen Therapeutics Division of Janssen Products

Faculty Disclosure

Primary Author

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar, MD, has disclosed that he has received consulting fees from Genentech, Gilead Sciences, Merck, and ViiV and funds for research support from Gilead Sciences, Merck, and ViiV.